These resources are intended for media professionals only and are factually correct at the time of issue.
-
Oct 6, 2023 • PRESS RELEASENew Griffith University site for the Translational Science HubSep 12, 2023 • JOINT PRESS RELEASETerryWhite Chemmart and Sanofi partner with The RUM Project to Promote Safe Responsible Medication DisposalAug 7, 2023 • PRESS RELEASESanofi releases Innovate Reconciliation Action PlanMay 2, 2023 • PRESS RELEASEWin-win for Sanofi with the promotion of two People & Culture ExecutivesApr 21, 2023 • PRESS RELEASESanofi is Australia’s 2023 AFR BOSS Best Place to Work in HealthApr 8, 2023 • PRESS RELEASEMajor Life Saving Drugs Program funding for rare genetic diseaseFeb 22, 2023 • PRESS RELEASESanofi Celebrates Sydney World PrideDec 5, 2022 • PRESS RELEASEMajor AUD280 million investment to deliver mRNA 2.0Dec 5, 2022 • PRESS RELEASESanofi encourages industry to unite in support of Return Unwanted Medicines this festive seasonNov 7, 2022 • PRESS RELEASELong-awaited overseas trips could be marred by infectious disease: expert warnsNov 1, 2022 • PRESS RELEASEFirst immunotherapy for patients with a potentially life-threatening type of non-melanoma skin cancer now available on the PBSOct 31, 2022 • PRESS RELEASEWe Volunteer - Sanofians reach over 800 volunteer hours in OctoberOct 14, 2022 • PRESS RELEASESanofi doubles commitment to solar with 3000 panels at Brisbane manufacturing campusSep 4, 2022 • PRESS RELEASEAustralia among world's best in treating debilitating and often fatal muscle disorderAug 30, 2022 • PRESS RELEASEWith Vaccines Community Grants awarded to support vaccine education & uptakeAug 22, 2022 • PRESS RELEASESanofi takes pride in first-in-industry Gender Affirmation PolicyAug 8, 2022 • PRESS RELEASESolar panel installation energizes Sanofi's climate ambitions down underJun 18, 2022 • PRESS RELEASEState-of-the-art augmented reality technology launches at Westmead Children’s Hospital to support those with HaemophiliaJun 12, 2022 • PRESS RELEASEFormer test cricketer Greg Matthews pitches it straight to mark Non-Melanoma Skin Cancer DayJun 1, 2022 • PRESS RELEASESanofi Australia Announces Industry-First Partnership with Return Unwanted MedicinesApr 30, 2022 • PRESS RELEASEPrioritise the young for flu vaccination, expert urgesApr 27, 2022 • PRESS RELEASEWith Vaccines Community Grants to inject $50,000 into value of vaccines educationMar 30, 2022 • PRESS RELEASEHigh-dose influenza vaccine for Australians aged 60+Mar 14, 2022 • PRESS RELEASELiz Siminsky appointed General Manager Specialty Care, Sanofi Australia & New ZealandMar 11, 2022 • PRESS RELEASESanofi supports supply of Japanese Encephalitis vaccine for AustraliaMar 8, 2022 • PRESS RELEASESanofi pledge $150,000 relief package for flood impacted communitiesMar 7, 2022 • PRESS RELEASESanofi joins the Business Council of AustraliaMar 2, 2022 • PRESS RELEASESanofi welcomes new Head of Supply Chain, Ruhul MoulaFeb 15, 2022 • PRESS RELEASESanofi Australia certified as Family Inclusive WorkplaceJan 24, 2022 • PRESS RELEASESanofi strengthens connection as part of Macquarie Park Innovation DistrictNov 24, 2021 • PRESS RELEASENational Vaccine Forum for primary healthcare professionalsOct 20, 2021 • PRESS RELEASESanofi Pasteur launches with VaccinesOct 13, 2021 • PRESS RELEASESanofi launches Its Possible for haemophilia communitySep 23, 2021 • PRESS RELEASESanofi celebrates 30th Anniversary of Sanofi Genzyme’s Humanitarian ProgramSep 9, 2021 • PRESS RELEASEDr Iris Depaz appointed Country Medical Lead Sanofi ANZAug 1, 2021 • PRESS RELEASEGovernment subsidises medicine to combat high cholesterol in high-risk AustraliansMay 27, 2021 • PRESS RELEASETaking Action Sanofi Australia launches Reflect Reconciliation Action PlanMay 20, 2021 • PRESS RELEASESanofi supports launch of National Flu Vaccination ProgramMay 4, 2021 • PRESS RELEASESanofi Genzyme partners with Invitae on new program to support greater access to genetic testingFeb 26, 2021 • PRESS RELEASETime to roll-up for flu shotFeb 28, 2021 • PRESS RELEASENew treatment era for patients with severe uncontrolled asthmaFeb 27, 2021 • PRESS RELEASEDupixent® PBS listed for severe atopic dermatitisFeb 24, 2021 • PRESS RELEASESanofi announced a leader in workplace gender equality ahead of International Women’s Day 2021Jan 27, 2021 • PRESS RELEASESanofi recognised as a Top Employer 2021 in AustraliaDec 15, 2020 • PRESS RELEASESanofi ranked one of Australia’s top 10 workplaces for DadsSep 18, 2020 • PRESS RELEASEHidden in broad daylight – the deadly impact of non-melanoma skin cancer in AustraliaSep 17, 2020 • PRESS RELEASESanofi awarded Platinum for Best Wellbeing Team and Best Wellbeing StrategyJul 22, 2020 • PRESS RELEASESanofi and The Smith Family continue to inspire Australian students with first virtual Work Inspiration ProgramJun 24, 2020 • PRESS RELEASESanofi Australia launches first Accessibility Inclusion PlanApr 26, 2020 • PRESS RELEASEFirst nationwide influenza vaccine program to target children aged 6 months to under five yearsMar 4, 2020 • PRESS RELEASESanofi continues its commitment to gender equality International Women’s Day 2020Feb 3, 2020 • PRESS RELEASEFirst in class atopic dermatitis medicine now available for adolescentsJan 13, 2020 • PRESS RELEASESanofi Australia commits more than $200,000 for bushfire affected communitiesSep 13, 2019 • PRESS RELEASESanofi Genzyme welcomes inquiry into allergic diseases in AustraliaAug 16, 2019 • PRESS RELEASESanofi and The Smith Family get behind National Science WeekMay 31, 2019 • PRESS RELEASEDupixent® (dupilumab) Registered in Australia for Moderate to Severe Asthma with Type 2 InflammationMay 25, 2019 • PRESS RELEASESanofi wins platinium award for employee wellbeing programApr 5, 2019 • PRESS RELEASEBig Win on 'Made in Australia' for Sanofi Consumer HealthcareMay 31, 2018 • PRESS RELEASELatest Sanofi Pasteur influenza vaccine shipment arrives in AustraliaApr 1, 2018 • PRESS RELEASEAlternative insulin therapy for adults living with diabetes listed on the PBS from 1 AprilFeb 5, 2018 • PRESS RELEASEFirst targeted biologic for moderate-to-severe atopic dermatitis registered in AustraliaFeb 18, 2018 • PRESS RELEASENew, high dose influenza vaccine available to over 65’s this influenza season
Media contacts
CORPORATE
loren.mcmurtrie@sanofi.com
+61 402 397 504
VACCINES
sarah.lindeman@sanofi.com
+61 417 354 310
SPECIALTY CARE
Rare Disease, Rare Blood Disorders, Oncology, Immunology
karyn.mcintosh@sanofi.com
+61 439 881 364
GENERAL MEDICINES
danielle.brennan@sanofi.com
+61 412 159 685
This contact page is for use by journalists only. If you are not a member of the media then please submit your inquiry via our Contact Us page.
You are leaving the www.sanofi.com.au website
This link will take you to a website to which our Privacy Policy does not apply. Sanofi Australia & New Zealand has no control over the contents of these sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them.
Do you wish to proceed?
You are leaving the www.sanofi.com.au website
You are about to visit another Sanofi website that is not governed by Australia & New Zealand regulatory.
Do you wish to proceed?
You are leaving the www.sanofi.com.au website
If you wish to access one of our Group website from another country, click Proceed.
Medical practices and regulations can be different from one country to another.
As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.
You are leaving the www.sanofi.com.au website
You are leaving the www.sanofi.com.au website
You are about to visit another Sanofi website that belongs to Sanofi in Australia & New Zealand.Do you wish to proceed?